Exploring the OBI Pharma ADC Assets & the GlycOBI™ Platform
Time: 2:30 pm
day: Day One
Details:
- Discover how OBI Pharma has developed a unique glycan ADC platform (GlycOBI™) to enable a site-specific conjugation, which is in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in various DAR
- Review how assets using the GlycOBI™ platform have the potential for improved in vivo efficacy, better safety profile, and enhanced stability in animal studies
- Share data about how Anti-Nectin-4, -TROP2, HER2, and bi-specific ADCs were developed based on OBI’s GlycOBI™ platform
